Reality Check: Are You US Investor-Ready?


Event Details


Is your company US investor ready? In this “Reality Check”, we invite you to engage with investors and experts for unfiltered and honest feedback.

Time: Tuesday, Sept 20th, 2022, 2:00 PM – 4:00 PM CET

Venue: Digital Meeting (link will be sent out to participants)

REGISTER HERE

Norwegian health tech and life science companies aiming for US market entry face numerous challenges, with market failure most often related to gaps in information, awareness, or proper diligence in market dynamics and implementation. And while many of the top global investors in health tech and life science reside in the US, approaching US investors differs from the ways in which you interact with Norwegian or Nordic investors.

Is your company US investor ready?

In this “Reality Check – Are you US investor ready?”, USA Next invites you to engage with investors and experts for unfiltered and honest feedback. We first explore differences between Nordic and US investors, how and when to approach US investors, and what to prepare to get their attention. We will then send 3 selected companies into a “Reality Check”, where our investors and experts offer direct, actionable feedback to a pitch. At the end of the session, we will hold an open QA between the audience and panel, so please come with questions!

Investors

Kathrine Mellis

Investment Professional, Hadean Ventures

Katherine is an Investment Professional with Hadean Ventures, responsible for deal sourcing, due diligence and management of active investments. She brings deep commercial insight and international experience with prior roles in strategy consulting, corporate development and investment banking

Pekka Simula

Partner, Innovestor
Innovestor is a Finnish investment company, focusing on venture capital and real estate. The company also offer corporate venturing services.

Jonathan P. Gertler

Managing Director, BioVentures
Jonathan P. Gertler joined BioVentures Medtech Funds in 2019 and is currently a Managing Director. He has over 35 years of scientific, clinical, entrepreneurial, transactional, and investment expertise in both academic medicine and in the life sciences sector. Dr. Gertler is also the co-founder, Managing Partner and CEO of Back Bay Life Science Advisors, a global life science consultancy and advisory group, and founder of three additional healthcare companies.

Kelsey Tsai

Vice President, Sandbox Clinical Ventures and the Blue Venture Funds

Kelsey Tsai is a Vice President of Sandbox Clinical Ventures and the Blue Venture Funds. She supports the Blue Venture Funds’ investments
in Thrive (now Exact Sciences), Onc.AI, Sempre Health, and Workit Health.

 

Tentative agenda:

14.00 – 14.05 Introduction to the topic

14.05 – 14.30 PANEL discussion: Nordic vs. US Readiness – what is different

14.30 – 15.30 Reality Check – Is YOUR company US investor ready?

  • 14.30 – 14.50 Company Pitch #1 with panel QA
  • 14.50 – 15.10 Company Pitch #2 with panel QA
  • 15.10 – 15.30 Company Pitch #3 with panel QA

15.30 – 15.45 Audience QA to investors

 

Investors: Hadean VenturesInnovestor, & more to be confirmed

Supported by:

 

Print This Post